CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 100.0%

Compliant submissions 1

Incompliant submissions 0

Total trials 1

My Organizations' Clinical Trials

Showing 175 of 279 entries

View as:

Ethnic/Racial Differences in Metabolism and DNA Adduct Formation

Phase: N/A Priority: Normal

NCT ID: NCT03421678 Org: User:

Start: 10/31/20 End: 06/30/23 Due: 06/30/24

Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease

Phase: N/A Priority: Normal

NCT ID: NCT00005998 Org: User:

Start: 01/31/00 End: 03/31/03 Due: 03/31/04

Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00903630 Org: User:

Start: 04/30/09 End: 08/31/11 Due: 08/31/12

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

Phase: N/A Priority: Normal

NCT ID: NCT03934840 Org: User:

Start: 10/10/19 End: 05/31/25 Due: 05/31/26

TBI Dose De-escalation for Fanconi Anemia

Phase: N/A Priority: Normal

NCT ID: NCT00352976 Org: User:

Start: 05/18/06 End: 10/09/20 Due: 10/09/21

Stem Cell Transplant for Hematological Malignancy

Phase: N/A Priority: Normal

NCT ID: NCT00176930 Org: User:

Start: 10/31/01 End: 12/31/19 Due: 12/31/20

Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00295880 Org: User:

Start: 06/30/05 End: 08/31/08 Due: 08/31/09

Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase: N/A Priority: Normal

NCT ID: NCT00818649 Org: User:

Start: 01/31/09 End: 05/31/12 Due: 05/31/13

CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant

Phase: N/A Priority: Normal

NCT ID: NCT00369291 Org: User:

Start: 09/30/03 End: 05/31/10 Due: 05/31/11

Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ

Phase: N/A Priority: Normal

NCT ID: NCT00290654 Org: User:

Start: 12/31/02 End: 03/31/13 Due: 03/31/14

Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal

NCT ID: NCT00620295 Org: User:

Start: 03/31/07 End: 10/31/09 Due: 10/31/10

UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

Phase: N/A Priority: Normal

NCT ID: NCT02722668 Org: User:

Start: 05/15/17 End: 12/31/29 Due: 12/31/30

Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00895414 Org: User:

Start: 04/30/09 End: 10/31/15 Due: 10/31/16

Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)

Phase: N/A Priority: Normal

NCT ID: NCT00167219 Org: User:

Start: 11/18/99 End: 08/09/23 Due: 08/09/24

MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients

Phase: N/A Priority: Normal

NCT ID: NCT02395822 Org: User:

Start: 10/01/15 End: 12/01/16 Due: 12/01/17

Vaccination With Tetanus and KLH to Assess Immune Responses.

Phase: N/A Priority: Normal

NCT ID: NCT00000105 Org: User:

Start: 07/31/02 End: 03/31/12 Due: 03/31/13

Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

Phase: N/A Priority: Normal

NCT ID: NCT01012362 Org: User:

Start: 12/31/09 End: 02/28/13 Due: 02/28/14

Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

Phase: N/A Priority: Normal

NCT ID: NCT00602446 Org: User:

Start: 08/31/07 End: 12/31/09 Due: 12/31/10

Radiation and Combination Immunotherapy for Melanoma

Phase: N/A Priority: Normal

NCT ID: NCT03850691 Org: User:

Start: 05/28/19 End: 12/12/22 Due: 12/12/23

NF-1, Nutraceutical Intervention

Phase: N/A Priority: Normal

NCT ID: NCT05363267 Org: User:

Start: 07/06/22 End: 08/31/26 Due: 08/31/27

Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT

Phase: N/A Priority: Normal

NCT ID: NCT02988466 Org: User:

Start: 01/24/17 End: 03/24/25 Due: 03/24/26

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Phase: N/A Priority: Normal

NCT ID: NCT03674411 Org: User:

Start: 01/02/19 End: 06/28/25 Due: 06/28/26

Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant

Phase: N/A Priority: Normal

NCT ID: NCT00305682 Org: User:

Start: 06/30/05 End: 12/12/19 Due: 12/12/20

Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies

Phase: N/A Priority: Normal

NCT ID: NCT03557749 Org: User:

Start: 09/21/18 End: 08/15/23 Due: 08/15/24

MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs

Phase: N/A Priority: Normal

NCT ID: NCT02582775 Org: User:

Start: 03/31/16 End: 07/26/23 Due: 07/26/24

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Ethnic/Racial Differences in Metabolism and DNA Adduct Formation	NCT03421678	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2020-10-31	2023-06-30	2024-06-30	-	-	2025-07-14
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease	NCT00005998	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2000-01-31	2003-03-31	2004-03-31	-	-	2025-07-14
Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	NCT00903630	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2009-04-30	2011-08-31	2012-08-31	-	-	2025-07-14
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone	NCT03934840	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2019-10-10	2025-05-31	2026-05-31	-	-	2025-07-14
TBI Dose De-escalation for Fanconi Anemia	NCT00352976	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2006-05-18	2020-10-09	2021-10-09	-	-	2025-07-14
Stem Cell Transplant for Hematological Malignancy	NCT00176930	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2001-10-31	2019-12-31	2020-12-31	-	-	2025-07-14
Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer	NCT00295880	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2005-06-30	2008-08-31	2009-08-31	-	-	2025-07-14
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia	NCT00818649	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2009-01-31	2012-05-31	2013-05-31	-	-	2025-07-14
CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant	NCT00369291	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2003-09-30	2010-05-31	2011-05-31	-	-	2025-07-14
Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ	NCT00290654	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2002-12-31	2013-03-31	2014-03-31	-	-	2025-07-14
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors	NCT00620295	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2007-03-31	2009-10-31	2010-10-31	-	-	2025-07-14
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep	NCT02722668	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2017-05-15	2029-12-31	2030-12-31	-	-	2025-07-14
Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer	NCT00895414	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2009-04-30	2015-10-31	2016-10-31	-	-	2025-07-14
Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)	NCT00167219	Masonic Cancer Center, University of Minnesota	user2@example.com	None	1999-11-18	2023-08-09	2024-08-09	-	-	2025-07-14
MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients	NCT02395822	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2015-10-01	2016-12-01	2017-12-01	-	-	2025-07-14
Vaccination With Tetanus and KLH to Assess Immune Responses.	NCT00000105	Masonic Cancer Center, University of Minnesota	user6@example.com	Compliant	2002-07-31	2012-03-31	2013-03-31	2025-07-01	-	2025-07-14
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors	NCT01012362	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2009-12-31	2013-02-28	2014-02-28	-	-	2025-07-14
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant	NCT00602446	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2007-08-31	2009-12-31	2010-12-31	-	-	2025-07-14
Radiation and Combination Immunotherapy for Melanoma	NCT03850691	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2019-05-28	2022-12-12	2023-12-12	-	-	2025-07-14
NF-1, Nutraceutical Intervention	NCT05363267	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2022-07-06	2026-08-31	2027-08-31	-	-	2025-07-14
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT	NCT02988466	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2017-01-24	2025-03-24	2026-03-24	-	-	2025-07-14
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy	NCT03674411	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2019-01-02	2025-06-28	2026-06-28	-	-	2025-07-14
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant	NCT00305682	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2005-06-30	2019-12-12	2020-12-12	-	-	2025-07-14
Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies	NCT03557749	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2018-09-21	2023-08-15	2024-08-15	-	-	2025-07-14
MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs	NCT02582775	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2016-03-31	2023-07-26	2024-07-26	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance